The ACE-I proven arena
One of the most important considerations for planning or designing a RCT is to determine whether the targeted patient population would already benefit from an existing treatment. In fact, ACE-I have already been shown to be quite effective in a number of diseases and populations. In these clinical entities, placebo comparisons are generally not in the best interest of our patients. Nevertheless, it is important to be able to assess the relative merits of these two inhibitors of the RAS. For clinical scenarios in which an ACE-I is already of proven benefit, three critical questions need to be addressed: First, is an ARB better than an ACE-I? Secondly, does an ARB offer incremental benefit over an ACE-I when the two therapies are used in combination? Thirdly, is an ARB clinically effective and safe in patients who are intolerant of ACE-I?
Is an ARB equivalent to or better than an ACE-I? ELITE II (Evaluation of Losartan in the Elderly) is the only completed RCT that has addressed whether an ARB was superior to an ACE-I. 12 Designed to test the hypothesis that the mortality benefit seen in the first ELITE 13 trial would hold up in a properly powered trial, 3152 elderly patients with systolic heart failure (HF) (ejection fraction (EF) ≤40%) were randomised to receive either losartan (50 mg daily) or captopril (50 mg t.d.s.). Following a median follow-up of 1.5 years, there was no statistical difference in the primary endpoint of all-cause mortality between the two groups. In fact, there was a non-significant decreased in mortality in the captopril group, compared with the losartan group (15.9 vs. 17.7%, p=0.16). Moreover, since it was designed as a superiority trial, the study did not have sufficient power to test for equivalence or non-inferiority. On the other hand, losartan was better tolerated than captopril, with a higher rate of withdrawal because of adverse events in the captopril group (14.5% vs. 9.4%, p<0.001). There are three major ongoing studies that directly compare an ARB to a proven dose of an ACE-I, two of which are in high-risk myocardial infarction (MI) patients. OPTIMAAL 14 (OPTIMal therapy in myocardial infarction with the Angiotensin II Antagonist Losartan) completed enrollment of 5477 patients with acute MI and signs of HF or left ventricular dysfunction. Patients were randomised to losartan or captopril to detect a potential difference in mortality with either of the RAS inhibitors.VALIANT 15 (VALsartan In Acute myocardial iNfarcTion) also completed its enrollment with 14,812 patients with acute MI, associated with either HF symptoms and/or left ventricular dysfunction (EF<40%).Although VALIANT has three randomisation arms (valsartan alone, captopril alone, or the combination of the two), it will provide a direct comparison between the effects of a proven dose of an ACE-I and those of an ARB on all-cause mortality. ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) is just commencing enrollment, with a goal of 23,400 patients with 'HOPE-like' high cardiovascular risk, such as a history of coronary artery disease, cerebrovascular disease, peripheral vascular disease or diabetes plus other risk factors. ONTARGET, like VALIANT, is a three-arm study, comparing the efficacy of telmisartan, either alone or in combination with ramipril, to ramipril alone. The primary endpoint is a composite of cardiovascular death, stroke, MI or CHF hospitalisation.
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Is there an additive effect of combining an ARB with and ACE-I?
The rationale behind this question is that more complete blockade of the RAS, with preservation or potentiation of the beneficial action of bradykinin, might be achieved by use of these two therapies in combination, rather than by an ACE-I alone. 16 Although several preclinical studies have shown beneficial effects of combined therapies on surrogate endpoints [17] [18] [19] (such as exercise capacity, neurohormonal levels and haemodynamic data), improvements in clinical outcomes must be demonstrated. Val-HeFT 20,21 (Valsartan in Heart Failure Trial) was the first of this design type to be presented. Val-HeFT enrolled 5010 patients with systolic HF and enlarged left ventricles on standard conventional therapy added to either valsartan or placebo. As such, patients were permitted, indeed expected, to be taking an ACE-I. The trial had two co-primary endpoints: 1) all-cause mortality and 2) a composite endpoint of death, resuscitated sudden death, HF hospitalisation or usage of intravenous inotropes or vasodilators. No difference in mortality was observed (valsartan vs. placebo, 495 (19.7%) vs. 484 (19.4%) deaths, p=0.8). However, a significant decrease in the other co-primary endpoint was obtained with valsartan (28.8% vs. 32.1%, p=0.009, relative risk reduction (RR) 13%) predominantly due to a reduction in hospitalisation for HF (13.9% vs. 18.5%, RR 27%). Since the small subset (7%) of patients who were not on ACE-I at baseline had the most striking benefit, the answer to the combination of therapies dilemma was less clear.
A component of the ongoing CHARM programme 22 (Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity) will also evaluate the potential benefit of combining ACE-I with ARBs in HF. Specifically, the CHARM 'Added' arm is comparing the efficacy of candesartan to placebo in reducing the primary endpoint of cardiovascular death or HF hospitalisation in 2548 patients with systolic HF (EF ≤40%) already receiving an ACE-I. The results of CHARM are expected in 2003.
Both VALIANT 15 and ONTARGET are also designed to directly address the 'add-on' hypothesis of ACE-I plus ARB. These ongoing trials have the additional design advantage of using a proven dose of an ACE-I (captopril or ramipril, respectively) to which an ARB (valsartan or telmisartan, respectively) is being added.
Is an ARB effective in the ACE-I intolerant populations?
Although estimates regarding intolerance of ACE-I range from 7% to over 30%, a large international registry of investigators' sites indicates that approximately 10% of patients are not on an ACE-I owing to prior problems. 23 The most common reasons for discontinuation are cough and symptomatic hypotension. Although an ARB is commonly perceived as an equal substitute, this assumption of clinical benefit must be proven. Results from major mortality RCTs are awaited with much eagerness to answer that question. As mentioned in Val-HeFT, 20 in the small subset of patients (7%) not receiving an ACE-I at baseline, randomisation to the ARB valsartan appeared to have reduced the risk of the combined mortality/morbidity endpoint compared with the patients on conventional therapy plus placebo, but not on ACE-I. Another component of the CHARM programme, 22 CHARM 'Alternative' has randomised 2028 patients with HF (EF ≤40%) intolerant of ACE-I, to either candesartan or placebo and should provide more definitive information on this important issue. In addition,TRAN-SCEND (Telmisartan Randomized AssessmeNt Study in ACE-I iNtolerant subjects with CV Disease), as part of the ONTARGET programme, will enrol 5000 ACE-I intolerant patients and will be evaluating the efficacy of telmisartan against placebo in reducing the composite endpoint of cardiovascular death, MI, stroke or HF hospitalisation in high-risk vascular patients that are considered intolerant of an ACE-I.
The ACE-I unproven arena
In disease entities, in which ACE inhibition has not 216 REVIEW shown meaningful improvements in clinical outcomes, ARBs are being actively compared with other commonly used agents, or are being studied against placebo in conditions where no particular therapy has been proven effective yet.
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Compared with other agents
Although first approved for blood pressure (BP) lowering, ACE-I have yet to be distinguished with a major long-term benefit on morbidity/mortality. As such, ARBs do not have to be compared with ACE-I to prove clinical effectiveness in hypertension.
In this population, two major RCTs with ARBs are using BP control, based on either a commonly used β-blocker or a calcium channel blocker. LIFE 24 (Losartan Intervention For Endpoint) has enrolled 9143 patients with hypertension and electrocardiographic left ventricular hypertrophy and compared the efficacy of the ARB, losartan, to the βblocker, atenolol, in reducing the composite endpoint of CV-death, MI or stroke.VALUE 25 (Valsartan Antihypertensive Long-term Use Evaluation trial of CV events in hypertension) is an even larger trial, that enrolled 15,314 hypertensive patients with an additional CV risk factor. Patients were randomised to either valsartan or the calcium channel blocker, amlodipine, with the primary endpoint being a composite of CV-death, MI, HF or urgent coronary revascularisation.
In patients with hypertension and diabetic nephropathy, a clear comparison between an ARB and a calcium channel blocker is already available. In IDNT 26 (Irbesartan type II Diabetic Nephropathy Trial) 1715 patients with hypertension and diabetes were randomised to three groups: placebo, irbesartan or amlodipine.Antihypertensive therapy, other than a calcium channel blocker or a RAS inhibitor, could and was added to control BP in all groups. The primary endpoint was a composite of doubling of serum creatinine, end-stage renal disease or death. Irbesartan reduced the relative risk of the primary endpoint by 20% vs. placebo and by 23% vs. amlodipine. In addition, since BP reduction was similar in all three arms, and indeed almost identical in the irbesartan and amlodipine groups, the observed renal benefits in the ARB group can be attributed to properties beyond that of BP reduction.
New potential uses vs. placebo
Targeting the same population, Type 2 diabetics with renal disease, RENAAL 27 (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) compared the efficacy of the ARB losartan to placebo plus other antihypertensive therapies in 1513 patients. The RENAAL investigators showed a 16% risk reduction in the combined risk of death, doubling of serum creatinine or need for dialysis and a 28% risk reduction in progression to end-stage renal disease. RENAAL and IDNT are consistent and impressive in their independent demonstration of the importance of ARBs in forestalling renal failure in high-risk patients. The recently completed IRMA II 28 (Irbesartan in patients with Type 2 diabetes and microalbuminuria study group) study underscores the clinical utility of ARBs even earlier in this disease process.
Heart failure with preserved systolic function, a common condition, has been neglected in most HF RCTs. As a consequence, there is a paucity of evidence on which to develop management guidelines for this syndrome. Fortunately, the CHARM programme 22 has an arm, CHARM 'Preserved', in which candesartan is being compared with placebo in 3025 patients with history of cardiovascular hospitalisation, symptomatic HF and an ejection fraction greater than 40%.
Other novel populations are being studied with ARBs. Enrolling elderly patients (70-89 years old) with optimal Mini-Mental Status Examination (>24), the SCOPE 29 study (Study on COgnition and Prognosis in the Elderly) is testing the hypothesis suggesting that the ARB candesartan, compared with placebo plus hydrochlorothiazide, could reduce the occurrence of CV-death, MI or stroke as primary endpoint. This trial will formally test the effects of the ARB on cognitive function and dementia.
DIRECT (DIabetic Retinopathy Candesartan Trials) will determine whether candesartan can influence the progression or the development of retinopathy in a trial of 4500 patients with Type 1 or Type 2 diabetes.
In NAVIGATOR (Nateglinide And Valsartan in Impaired Glucose Tolerance Outcome tRial), 7500 patients with impaired glucose tolerance and cardiovascular risk will be randomised, in a 2 x 2 factorial design, to valsartan and nateglinide. The objective of this RCT is to evaluate the effect of therapy on the development of diabetes in this pre-diabetic population.The secondary endpoints include CV-death, MI, stroke, need for revascularisation or unstable angina.
The development of ARBs as an additional pharmacological means of inhibiting the RAS offers a host of opportunities to improve patient care. These agents appear safe and well-tolerated. The main interrogation is whether this novel class of pharmacologic therapy will add substantial value in the management of patients already on optimal care by current standards. Fortunately for physicians and patients, an impressive array of RCTs with ARBs will undoubtedly demonstrate the true value of these agents across a broad spectrum of diseases ( Figure 3 ). 
